September 25th 2023
Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.
September 25th 2023
In this Contemporary Pediatrics interview, James Wallace, MD, discusses increased trends in school avoidance and the negative effects associated with less days in the classroom.
Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
The FDA issued the Complete Response Letter (CRL) based on the request for a completed pharmacokinetic/pharmacodynamic study to assess how repeat doses of the epinephrine nasal spray compare to repeat doses of an epinephrine injection product. ARS Pharma is set to file a Formal Dispute Resolution Request to appeal the CRL.
Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.
According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regards to their children's health.
Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2023 flu season are quadrivalent.
Surveys collected for a study published in the Canadian Journal of Diabetes revealed that desire for telehealth care amid pediatric diabetes families increased from the early onset of the COVID-19 pandemic, to more than 1 year later.
A supplemental biologics license application for ALTUVIIIO (Antihemophilic factor; Sanofi) has been accepted by the FDA for use in patients aged 12 years and younger with severe hemophilia A.